The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 1, 1999, Pages 78-81

  Shimizu, Masafumi ^a   Wang, Qing Dong ^a   Sjöquist, Per Ove ^a   Rydén, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin II; AT1 receptor Myocardium; Candesartan; Heart; Ischemia; Rat; Reperfusion

Indexed keywords

CANDESARTAN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; BLOOD PRESSURE; CORONARY BLOOD VESSEL; DRUG ANTAGONISM; HEART; IN VITRO STUDY; PHYSIOLOGY; REPERFUSION INJURY; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; CORONARY VESSELS; HEART; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; REPERFUSION INJURY; TETRAZOLES;

EID: 0032588175     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199907000-00013     Document Type: Article

References (21)

1. Bermann MA, Walsh MF, Sowers JR. Angiotensin-II biochemistry and physiology: update on angiotensin-II receptor blockers. Cardiovasc Drug Rev 1997;15:75-100.
2. Grinstead WC, Young JB. The myocardial renin-angiotensin system: existence, importance, and clinical implications. Am Heart J 1992;123:1039-45.
3. Ferrario CM, Flack JM. Pathologic consequences of increased angiotensin II activity. Cardiovasc Drug Ther 1996;10:511-8.
4. de Graeff PA, van Gilst WH, Wesseling H. The cardiac renin-angiotensin system in different ischemic syndromes of the heart. In: Lindpainter K, Ganten D, eds. The cardiac renin-angiotensin system. New York: Futura Publishing, 1994:201-31.
5. Martorana P, Kettenbach B, Breipohl G, Linz W, Schölkens BA. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by bradykinin antagonist. Eur J Pharmacol 1990;182:395-6.
6. Werrmann JG, Cohen SM. Use of losartan to examine the role of the cardiac renin-angiotensin system in myocardial dysfunction during ischemia and reperfusion. J Cardiovasc Pharmacol 1996; 27:177-82.
7. Yang BC, Phillips MI, Ambuehl PEJ, Shen LP, Mehta P, Mehta J. Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in rat isolated hearts. Circulation 1997; 96:922-6.
8. Senzaki H, Gluzband YA, Pak PH, Crow MT, Janicki JS, Kass DA. Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II. Circ Res 1998;82:503-12.
9. Mochizuki T, Eberli FR, Apstein CS, Lorell BH. Exacerbation of ischemic dysfunction by angiotensin II in red cell-perfused rabbit hearts. J Clin Invest 1992;89:490-8.
10. Yoshiyama M, Kim S, Yamagishi H, et al. The deleterious effects of exogenous angiotensin I and angiotensin II on myocardial ischemia-reperfusion injury. Jpn Circ J 1994;58:362-8.
11. Kinugawa K, Kohmoto O, Serizawa T, Takahashi T. CV-11974: a nonpeptide angiotensin II type 1 receptor antagonist. Cardiovasc Drug Rev 1997;15:59-74.
12. Sjöquist P-O, Abrahamsson T, Johansson MH. Time course of regional flow distribution following reperfusion of the isolated ischemic rat heart. Clin Exp Pharmacol Physiol 1992;19:249-52.
13. Neely JR, Liebermeister H, Battersby EJ, Morgan HE. Effect of pressure development on oxygen consumption by isolated rat heart. Am J Physiol 1967;212:804-14.
14. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodeling in myocardial-infarcted rats. J Mol Cell Cardiol 1993;25: 1369-80.
15. 2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 1996;94:3087-9.
16. Shimizu M, Wang Q-D, Sjöquist P-O, Rydén L. Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury. J Cardiovasc Pharmacol 1998;32:231-8.
17. Humphrey SM, Thomson RW, Gavin JB. The influence of the no-reflow phenomenon on reperfusion and reoxygenation damage and enzyme release from anoxic and ischemic isolated rat hearts. J Mol Cell Cardiol 1984;16:915-30.
18. 2-receptors in endothelial cells and isolated ischemic rat heart. Pharm Pharmacol Lett 1993;3:24-7.
19. Tada H, Egashira K, Yamamoto M, et al. Glibenclamide: a specific inhibitor of ATP-sensitive K channel, inhibits coronary vasodilation induced by angiotensin II-receptor antagonists. J Cardiovasc Pharmacol 1997;30:313-9.
20. 1 receptor-mediated pressor and chronotropic effects. J Clin Invest 1998;101:527-35.
21. Hein L, Barsh G, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 1995;377:744-7.